The Insider For Teva Pharmaceutical Industries Limited (TEVA) Sold 50,860 Shares.

The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) decreased by remained unchanged at $10.13, down -0.10 percent. The last five days have seen an average of 6,362,320 shares of common stock traded. 9 times new highs were reached in the current year, with a gain of $0.48. The average number of shares traded over the last 20 days was 7,329,965, while the average volume over the last 50 days totaled 6,802,418.

TEVA stock appreciated 11.93% since last month. On 09/23/21, the company’s shares reached a one-month low of $8.74. The stock touched a high of $13.30 on 02/09/21, after rallying from a low of $8.24 in 52 weeks. The price of TEVA stock has risen by 4.97% or $0.48 this year, reaching a new high 9 times. Still, the stock price is down -23.83% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

There have been 76 days since Teva Pharmaceutical Industries Limited (TEVA) last reported insider trading activity on Aug 10. On Aug 10, Executive VP, Global R&D Fridriksdottir Hafrun sold 50,860 shares at $9.95 each. This transaction resulted in the insider making $506,021. On May 21, Drape Eric sold 40,000 shares at a price of US$11.01. After the transaction, the insider now owns 33,128 shares. Exec. VP Chief Legal Officer Stark David Matthew had earlier sold 37,884 shares on May 11 for $10.22 a share. The transaction was completed for $387,125.

Valuation Metrics

The PE ratio of Teva Pharmaceutical Industries Limited has varied between 3295.00 and 20.37 in the last five years. Beta for the stock is 1.36. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 0.69, the price-to-book (PB) ratio of 1.08.

Teva Pharmaceutical Industries Limited’s dividend is $0.34 per share per year. On Dec. 12, the company paid $0.0850 per share in dividends, remained unchanged from $0.0850 last year. A $0.2550 dividend decrease was reported on Monday August 7 2017.

For the three months ended June 29, Teva Pharmaceutical Industries Limited’s quick ratio was 0.70, while its current ratio was 1.00, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 2.09, and the total debt to equity ratio is 2.43. As far as profitability goes, gross margin for the trailing twelve months is 47.60% percent. Teva Pharmaceutical Industries Limited’s EBITDA margin for the year ended June 29 was 27.70%, whereas its operating margin stood at -17.90% for the same period. Based on annual data, it had gross profit of $7.73 billion and revenue of $16.66 billion.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TEVA’s return on assets (ROA) during the last 12 months has been -7.90%. There was a -9.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -39.20%. ROE has averaged -15.50 in the past year for the broader industry.

Earnings Surprise

According to Teva Pharmaceutical Industries Limited’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $3.91 billion, while revenues rose by 1.02% to $3.98 billion. It was predicted that Teva Pharmaceutical Industries Limited’s quarterly earnings would be $0.59, but it ended up being $0.59. EBITDA was $887.0 million for the quarter. At the end of Teva Pharmaceutical Industries Limited’s most recent quarter ended June 29, its liabilities totaled 37.88 billion, while its total debt was $25.58 billion. Equity owned by shareholders amounts to $1.1 billion.

Technical Picture

Here’s a quick look at Teva Pharmaceutical Industries Limited’s (TEVA) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 65.39%, suggesting the stock is Neutral, with a 25.84% historical volatility rate.

The stochastic %K and %D were 80.56% and 75.12% respectively, while the average true range (ATR) was 0.25. Based on the 14-day stochastic reading of 77.27%, the RSI (14) reading is 62.22%. On the 9-day MACD Oscillator, the stock is at 0.21, and the 14-day reading is at 0.18.

Analyst Ratings

Teva Pharmaceutical Industries Limited (NYSE: TEVA) was downgraded by UBS to a a Neutral rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned Teva Pharmaceutical Industries Limited (TEVA) an Hold rating. TEVA is a stock that is recommended for selling by 0 brokerage firms, while 13 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 2 rates it overweight and 1 other recommend it as a buy.

What is TEVA’s price target for the next 12 months?

The current consensus forecast for the stock is between $10.00 and $14.00, with a median target price of $11.00. In analyzing these forecasts, the average price target given by analysts for Teva Pharmaceutical Industries Limited (TEVA) is $11.54.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam